Kleanthis Xanthopoulos

Kleanthis G.
Xanthopoulos was the founder of Anadys Pharmaceuticals, Inc., founded in 1992, where the title held was Director from 2006 to 2011.
Dr. Xanthopoulos is the founder of Senté, Inc., founded in 2007, holding the title of Executive Chairman starting in 2026.
Dr. Xanthopoulos is the founder of SENTÉ Labs, founded in 2007, holding the title of Director.
Dr. Xanthopoulos is also the founder of Shoreline Biosciences, Inc...
Current jobs include Chairman at Stork Capital SARL since 2020, Chairman at Connect Biopharma Holdings Ltd. since 2024, Director at Irras AB since 2021, Director at Suzhou Connect Biopharma Co. Ltd. since 2020, President at Helios, Inc., and Managing Partner at Vandel Group LLC.
Former jobs include President, Chief Executive Officer & Director at Regulus Therapeutics, Inc. in 2015; Chairman at Apricus Biosciences, Inc. from 2013 to 2019; Chairman at Bioniz Therapeutics, Inc. in 2016; Director at ZP Opco, Inc.; Director at Biotechnology Innovation Organization; Director at J.E.M.
Capital, Inc. from 2013 to 2014; Managing Director at Enterprise Partners Venture Capital in 2007; Director at Odyssey Thera, Inc.; Director at Aspirus, Inc.; Director at Laboratori Derivati Organici SpA from 2016 to 2017; Independent Director at Zosano Pharma Corp.
from 2013 to 2021; Executive Director at Biocom, Inc. in 2014; Senior Vice President at Ionis Pharmaceuticals, Inc.; Vice President-Genomics & Molecular Biology at Aurora Biosciences Corp.
from 1997 to 2000; Associate Professor at Karolinska Institutet; Section Head at National Human Genome Research Institute from 1995 to 1997; Managing General Partner at Cerus Advisors DMCC from 2015 to 2020.
Education includes a doctorate conferred in 1986 and a graduate degree conferred in 1982 from the University of Stockholm, and an undergraduate degree conferred in 1980 from Aristotle University of Thessaloniki.